Table 1. Mean (± SD) plasma concentration of α-MG after intravenous and oral administration of α-MG to mice.
| Parameters Intravenous | 5 mg/kg (n = 9) | 10 mg/kg (n = 8) | 20 mg/kg (n = 8) |
| Body weight (g) | 30.9 ± 5.67 | 36.4 ± 6.87 | 33.3 ± 3.46 |
| AUC (μg min/mL) a | 169 ± 42.7 | 340 ± 99.4 | 633 ± 226 |
| Normalized AUC (μg min/mL) b | 33.8 ± 8.53 | 32.1 ± 8.91 | 31.7 ± 11.3 |
| Terminal half-life (min) | 226 ± 34.3 | 219 ± 73.8 | 173 ± 71.9 |
| MRT (min) | 145 ± 27.7 | 160 ± 67.0 | 144 ± 68.5 |
| CL (mL/min/kg) | 31.4 ± 7.28 | 31.3 ± 7.95 | 34.7 ± 12.4 |
| CLR (mL/min/kg) | 0.283 ±0.194 | 0.205 ± 0.150 | 0.141 ± 0.0801 |
| CLNR (mL/min/kg) | 31.1 ± 7.14 | 31.1 ± 7.83 | 34.6 ± 12.3 |
| V ss (mL/kg) | 4304 ± 1005 | 4270 ± 1974 | 4500 ± 1381 |
| Ae 0–24 h (% of dose) | 0.839 ± 0.525 | 0.592 ± 0.394 | 0.403 ± 0.163 |
| GI 24 h (% of dose) | 3.44 ± 1.16 | 2.28 ± 1.96 | 3.42 ± 1.73 |
| Parameters | 10 mg/kg (n = 8) | 50 mg/kg (n = 7) | 100 mg/kg (n = 9) |
| Oral | |||
| Body weight (g) | 25.0 ± 0.310 | 25.3 ± 1.89 | 27.9 ± 3.62 |
| AUC (μg min/mL) a | 7.80 ± 2.58 | 37.3 ± 10.5 | 83.2 ± 23.8 |
| Normalized AUC (μg min/mL) b | 0.861 ± 0.258 | 0.746 ± 0.209 | 0.831 ± 0.274 |
| Terminal half-life (min) | 177 ± 71.1 | 197 ± 81.0 | 151 ± 49.3 |
| C max (μg/mL) a | 0.0403 ± 0.0307 | 0.242 ± 0.0350 | 0.709 ± 0.397 |
| Normalized C max (μg/mL) b | 0.00403 ± 0.00306 | 0.00484 ± 0.000698 | 0.00708 ± 0.00396 |
| T max (min) c | 60 (15–120) | 30 (15–60) | 60 (15–360) |
| CLR (mL/min/kg) | 0.535 ± 0.309 | 0.547 ± 0.309 | 0.418 ± 0.229 |
| Ae 0–24 h (% of dose) | 0.0255 ± 0.0107 | 0.0315 ± 0.0241 | 0.0270 ± 0.0113 |
| GI 24 h (% of dose) | 43.5 ± 10.6 | 40.2 ± 11.6 | 41.2 ± 4.51 |
| F (%) | 2.29 | ||
All values were statistically analyzed and all of them were not statistically different (p < 0.05) except AUC and Cmax values among three doses.
a Statistically different (p < 0.05) among three doses.
b Normalized values based on 1 mg/kg were not statistically different among three doses.
c Median (ranges) for T max.